Table 1.
General characteristics of the target population according to CD4 count (left panel) and CD4/CD8 ratio (right panel) at the time of first vaccination.
| CD4 Count at the Time of First Vaccination | CD4/CD8 Ratio at the Time of First Vaccination | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Characteristics | LCD4 N = 77 |
ICD4 N = 298 |
HCD4 N = 801 |
p * | LR N = 381 |
IR N = 375 |
HR N = 420 |
p * | Total N = 1176 |
| Female, n (%) | 14 (18.2) | 55 (18.5) | 175 (21.8) | 0.397 | 66 (17.3) | 71 (18.9) | 107 (25.5) | 0.010 | 244 (20.7) |
| Age, years, median (IQR) | 56 (48, 59) | 54 (45, 61) | 52 (44, 58) | 0.013 | 53 (44, 60) | 53 (45, 59) | 52 (44, 59) | 0.485 | 53 (44, 59) |
| Caucasian, n (%) | 57 (74.0) | 240 (80.5) | 747 (93.3) | <0.001 | 307 (80.6) | 348 (92.8) | 389 (92.6) | <0.001 | 1044 (88.8) |
| ≥1 comorbidity, n (%) | 34 (44.2) | 108 (36.2) | 224 (28.0) | 0.001 | 129 (33.9) | 130 (34.7) | 107 (25.5) | 0.008 | 366 (31.1) |
| N. of comorbidities &, median (IQR) | 1 (1, 2) | 1 (1, 2) | 1 (1, 2) | 0.964 | 1 (1, 2) | 1 (1, 2) | 1 (1, 2) | 0.376 | 1 (1, 2) |
| AIDS, n (%) | 30 (39.0) | 130 (43.8) | 208 (26.1) | <0.001 | 164 (43.0) | 110 (29.5) | 94 (22.5) | <0.001 | 368 (31.4) |
| Time from HIV diagnosis, years, median (IQR) | 11 (1, 24) | 9 (4, 21) | 11 (6, 21) | 0.005 | 7 (3, 21) | 12 (7, 21) | 11 (7, 21) | <0.001 | 11 (5, 21) |
| Time from AIDS diagnosis, years, median (IQR) | 4 (2, 9) | 5 (2, 9) | 8 (5, 12) | 0.019 | 5 (2, 7) | 7 (4, 10) | 11 (7, 19) | <0.001 | 6 (3, 10) |
| Nadir CD4 count, cells/mm3, median (IQR) | 39 (12, 72) | 87 (34, 177) | 272 (115, 412) | <0.001 | 68 (28, 166) | 217 (92, 320) | 312 (155, 464) | <0.001 | 189 (57, 348) |
| CD4 count at first vaccination, cells/mm3, median (IQR) | 116 (61, 154) | 357 (275, 436) | 746 (587, 944) | <0.001 | 349 (206, 525) | 622 (479, 790) | 807 (628, 1015) | <0.001 | 606 (397, 838) |
| CD4 count at first booster dose, cells/mm3, median (IQR) | 160 (109, 210) | 378 (296, 443) | 749 (596, 944) | <0.001 | 385 (228, 509) | 678 (477, 837) | 798 (600, 1034) | <0.001 | 597 (391, 832) |
| CD4/CD8 ratio at first vaccination, cells/mm3, median (IQR) | 0.2 (0.1, 0.2) | 0.5 (0.3, 0.8) | 1.0 (0.7, 1.3) | <0.001 | 0.4 (0.2, 0.5) | 0.8 (0.7, 0.9) | 1.3 (1.1, 1.6) | <0.001 | 0.8 (0.5, 1.2) |
| CD4/CD8 ratio at first booster dose, cells/mm3, median (IQR) | 0.2 (0.1, 0.3) | 0.5 (0.4, 0.7) | 0.9 (0.7, 1.3) | <0.001 | 0.4 (0.3, 0.5) | 0.8 (0.7, 0.9) | 0.0 (0.0, 1.3) | <0.001 | 0.0 (0.0, 1.5) |
| HIV-RNA at first vaccination ≤ 50 cps/mL, n (%) | 50 (64.9) | 268 (90.2) | 778 (97.3) | <0.001 | 328 (86.1) | 361 (96.5) | 407 (97.1) | <0.001 | 1096 (93.4) |
| HIV-RNA at first booster dose ≤ 50 cps/mL, n (%) | 33 (84.6) | 111 (94.1) | 282 (95.3) | 0.031 | 147 (93.0) | 141 (93.4) | 138 (95.8) | 0.542 | 426 (94.0) |
| Having Antiretroviral Therapy | 73 (94.8) | 293 (98.3) | 788 (98.5) | 0.064 | 373 (97.9) | 368 (98.4) | 413 (98.3) | 0.853 | 1154 (98.2) |
| Vaccination times (days), medians (IQR) | |||||||||
| From second dose to response | 30 (28.0, 31.0) | 31 (30.0, 35.0) | 31 (29.0, 39.0) | 0.009 | 31 (30.0, 35.0) | 31 (29.0, 37.0) | 31 (29.0, 39.0) | 0.805 | 31 (29.0, 37.0) |
| From second dose to third dose | 158 (154.0, 166.0) | 177 (152.0, 209.0) | 189 (168.0, 216.0) | <0.001 | 167 (154.0, 201.5) | 187 (166.0, 217.0) | 190 (171.0, 213.0) | <0.001 | 183 (160.0, 212.0) |
| From third dose to response | 17 (15.0, 20.5) | 16 (14.0, 20.0) | 16 (14.0, 19.0) | 0.094 | 16 (14.0, 20.0) | 16 (14.0, 20.0) | 16 (14.0, 19.0) | 0.339 | 16 (14.0, 20.0) |
& Comorbidities considered: chronic kidney disease, chronic obstructive pulmonary disease, myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic cognitive deficit, connective tissue disease, peptic ulcer disease, chronic liver disease and end-stage liver disease, diabetes mellitus and diabetes with organ damage, hemiplegia, solid cancers with or without metastasis, hematological cancer; * chi-square or Kruskal–Wallis test, as appropriate.